Acute Promyelocytic Leukemia
34
4
6
10
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
8.8%
3 terminated out of 34 trials
76.9%
-9.6% vs benchmark
26%
9 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (34)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Frontline Oral Arsenic Trioxide for APL
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Optimum Induction Therapy of Low-risk APL
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
AIDA 2000 Guidelines
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
All-trans Retinoic Acid, and Arsenic +/- Idarubicin